PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsOrgotein
Orgotein
Orgotein is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AX: Other antiinflammatory and antirheumatic agents, non-steroids in atc
— M01AX14: Orgotein
HCPCS
No data
Clinical
Clinical Trials
115 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PeriodontitisD010518EFO_0000649K05.3—1—236
Diabetes mellitusD003920EFO_0000400E08-E13—11135
Sphincter of oddi dysfunctionD046628————1124
Type 2 diabetes mellitusD003924EFO_0001360E11—11124
Chronic periodontitisD055113EFO_0006343K05.3—1—1—2
FrailtyD000073496—R53.1———1—1
Male breast neoplasmsD018567—————1—1
Postoperative painD010149—G89.18———1—1
ParesthesiaD010292—R20.2———1—1
Postcholecystectomy syndromeD017562EFO_1001117K91.5———1—1
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amyotrophic lateral sclerosisD000690EFO_0000253G12.211054—923
Motor neuron diseaseD016472EFO_0003782G12.21053—922
SclerosisD012598——942—819
Head and neck neoplasmsD006258——1—1——2
StomatitisD013280EFO_1001904K12.1—11——2
MucositisD052016EFO_1001898——11——2
Prostatic neoplasmsD011471—C61——1—12
Postoperative complicationsD011183———11——2
FatigueD005221—R53.83——1—12
BacteremiaD016470EFO_0003033R78.81——1——1
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———61——18
Peripheral nervous system diseasesD010523—G64—1——23
Diabetic neuropathiesD003929EFO_1000783——1——23
Breast neoplasmsD001943EFO_0003869C50—1——12
Periodontal diseasesD010510—K05.6—1——12
Lung neoplasmsD008175—C34.9011———1
Wounds and injuriesD014947—T14.8—1———1
Reperfusion injuryD015427———1———1
Myocardial reperfusion injuryD015428EFO_0002687——1———1
DermatitisD003872—L30.911———1
Show 6 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Oxidative stressD018384EFO_1001905—1———67
Male infertilityD007248EFO_0004248N461———23
InfertilityD007246EFO_0000545—1———23
InflammationD007249MP_0001845—1———12
CarcinomaD002277—C80.01————1
Squamous cell carcinoma of head and neckD000077195——1————1
Squamous cell carcinomaD002294——1————1
Squamous cell neoplasmsD018307——1————1
Sleep apnea syndromesD012891EFO_0003877G47.31————1
HypoxiaD000860—R09.021————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Muscle strengthD053580——————33
Resistance trainingD055070——————33
Lung diseasesD008171EFO_0003818J98.4————22
PneumoniaD011014EFO_0003106J18————22
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9————22
Body compositionD001823——————22
Dental cariesD003731EFO_0003819K02————22
Lipid peroxidationD015227——————11
EndoscopyD004724——————11
Cardiovascular diseasesD002318EFO_0000319I98————11
Show 69 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOrgotein
INNorgotein
Description
Superoxide dismutase (SOD, EC 1.15.1.1) is an enzyme that alternately catalyzes the dismutation (or partitioning) of the superoxide (O−2) radical into ordinary molecular oxygen (O2) and hydrogen peroxide (H2O2). Superoxide is produced as a by-product of oxygen metabolism and, if not regulated, causes many types of cell damage. Hydrogen peroxide is also damaging and is degraded by other enzymes such as catalase. Thus, SOD is an important antioxidant defense in nearly all living cells exposed to oxygen. One exception is Lactobacillus plantarum and related lactobacilli, which use a different mechanism to prevent damage from reactive O−2.
Classification
Unknown
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108545
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDPKE82W49V1 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 103,022 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use